ALPHA ONE ANTITRYPSIN DEFICIENCY

Drug development companies are regularly contacting us to take part in new clinical trials for improved alpha one antitrypsin deficiency treatments, and we are keen to do so, as this provides Western Australians with alpha one antitrypsin deficiency the opportunity to access new treatments.

If you suffer from alpha one antitrypsin deficiency and would like to be considered for enrolment for participation in a clinical trials, please contact us by telephoning 9346 4964, email This e-mail address is being protected from spambots. You need JavaScript enabled to view it or click here to register online.

Study outline	Recruitment status
CE1226_4001: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase III/IV Study to compare the Efficacy and Safety of 60 mg/kg body weight of Zemaira® weekly i.v. administration with Placebo weekly i.v. administration in Chronic Augmentation and Maintenance Therapy in Subjects with Emphysema due to Alpha1-Proteinase Inhibitor Deficiency	Recruiting closed
CE1226_3001: An open, non-controlled, multicenter, multinational Study to Evaluate the Efficacy and Safety of Zemaira® administration in Chronic Augmentation and Maintenance Therapy in Participants with Emphysema due to Alpha1- Proteinase Inhibitor Deficiency who completed Clinical Study CE1226_4001.	Recruiting closed